FEBUFLIT-40 contains Febuxostat 40 mg, a selective xanthine oxidase inhibitor formulated for effective reduction of elevated uric acid levels and long-term gout management. A focused PCD Pharma anti-inflammatory/gout-care portfolio product.
Long-term management of hyperuricemia in gout.
No; it lowers uric acid over time.
Take regularly as prescribed and monitor serum uric acid and liver function when advised. Acute gout flares can occur when treatment is initiated; follow the physician’s advice regarding flare prophylaxis.
Nausea, diarrhea, headache, rash, joint-related discomfort and abnormal liver function tests may occur.
FEBUFLIT-40: Febuxostat selectively inhibits xanthine oxidase, reducing uric acid production and helping lower elevated serum uric acid levels.
